Genetic susceptibility, obesity and lifetime risk of type 2 diabetes: The ARIC study and Rotterdam Study

Symen Ligthart; Natalie R. Hasbani; Fariba Ahmadizar; Thijs T.W. van Herpt; Maarten J.G. Leening; André G. Uitterlinden; Eric J.G. Sijbrands; Alanna C. Morrison; Eric Boerwinkle; James S. Pankow; Elizabeth Selvin; M. Arfan Ikram; Maryam Kavousi; Paul S. de Vries; Abbas Dehghan

doi:10.1111/dme.14639

Genetic susceptibility, obesity and lifetime risk of type 2 diabetes: The ARIC study and Rotterdam Study

Symen Ligthart, Natalie R. Hasbani, Fariba Ahmadizar, Thijs T.W. van Herpt, Maarten J.G. Leening, André G. Uitterlinden, Eric J.G. Sijbrands, Alanna C. Morrison, Eric Boerwinkle, James S. Pankow, Elizabeth Selvin, M. Arfan Ikram, Maryam Kavousi, Paul S. de Vries, Abbas Dehghan

Epidemiology & Community Health

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Aims: Both lifestyle factors and genetic background contribute to the development of type 2 diabetes. Estimation of the lifetime risk of diabetes based on genetic information has not been presented, and the extent to which a normal body weight can offset a high lifetime genetic risk is unknown. Methods: We used data from 15,671 diabetes-free participants of European ancestry aged 45 years and older from the prospective population-based ARIC study and Rotterdam Study (RS). We quantified the remaining lifetime risk of diabetes stratified by genetic risk and quantified the effect of normal weight in terms of relative and lifetime risks in low, intermediate and high genetic risk. Results: At age 45 years, the lifetime risk of type 2 diabetes in ARIC in the low, intermediate and high genetic risk category was 33.2%, 41.3% and 47.2%, and in RS 22.8%, 30.6% and 35.5% respectively. The absolute lifetime risk for individuals with normal weight compared to individuals with obesity was 24% lower in ARIC and 8.6% lower in RS in the low genetic risk group, 36.3% lower in ARIC and 31.3% lower in RS in the intermediate genetic risk group, and 25.0% lower in ARIC and 29.4% lower in RS in the high genetic risk group. Conclusions: Genetic variants for type 2 diabetes have value in estimating the lifetime risk of type 2 diabetes. Normal weight mitigates partly the deleterious effect of high genetic risk.

Original language	English (US)
Article number	e14639
Journal	Diabetic Medicine
Volume	38
Issue number	10
DOIs	https://doi.org/10.1111/dme.14639
State	Published - Oct 2021

Bibliographical note

Funding Information:
The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL059367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The Rotterdam Study is supported by Erasmus MC and Erasmus University Rotterdam; Netherlands Organisation for Scientific Research (NWO); Netherlands Organisation for Health Research and Development (ZonMW); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative; Ministry of Education, Culture and Science; Ministry of Health, Welfa re and Sports; European Commission (DG XII); and Municipality of Rotterdam. None of the funders had any role in study design, study conduct; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. The dedication, commitment and contribution of inhabitants, general practitioners and pharmacists of the Ommoord district to the Rotterdam Study are gratefully acknowledged. PSdV and NRH were additionally supported by the American Heart Association grant number 18CDA34110116.

Publisher Copyright:
© 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

Keywords

BMI
lifetime risk
obesity
polygenic score
type 2 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1111/dme.14639

Find It

Find It at U of M Libraries

Cite this

Ligthart, S., Hasbani, N. R., Ahmadizar, F., van Herpt, T. T. W., Leening, M. J. G., Uitterlinden, A. G., Sijbrands, E. J. G., Morrison, A. C., Boerwinkle, E., Pankow, J. S., Selvin, E., Arfan Ikram, M., Kavousi, M., de Vries, P. S., & Dehghan, A. (2021). Genetic susceptibility, obesity and lifetime risk of type 2 diabetes: The ARIC study and Rotterdam Study. Diabetic Medicine, 38(10), Article e14639. https://doi.org/10.1111/dme.14639

Ligthart, S, Hasbani, NR, Ahmadizar, F, van Herpt, TTW, Leening, MJG, Uitterlinden, AG, Sijbrands, EJG, Morrison, AC, Boerwinkle, E, Pankow, JS, Selvin, E, Arfan Ikram, M, Kavousi, M, de Vries, PS & Dehghan, A 2021, 'Genetic susceptibility, obesity and lifetime risk of type 2 diabetes: The ARIC study and Rotterdam Study', Diabetic Medicine, vol. 38, no. 10, e14639. https://doi.org/10.1111/dme.14639

@article{6ed69db164b742c6a625a771ba949caf,

title = "Genetic susceptibility, obesity and lifetime risk of type 2 diabetes: The ARIC study and Rotterdam Study",

abstract = "Aims: Both lifestyle factors and genetic background contribute to the development of type 2 diabetes. Estimation of the lifetime risk of diabetes based on genetic information has not been presented, and the extent to which a normal body weight can offset a high lifetime genetic risk is unknown. Methods: We used data from 15,671 diabetes-free participants of European ancestry aged 45 years and older from the prospective population-based ARIC study and Rotterdam Study (RS). We quantified the remaining lifetime risk of diabetes stratified by genetic risk and quantified the effect of normal weight in terms of relative and lifetime risks in low, intermediate and high genetic risk. Results: At age 45 years, the lifetime risk of type 2 diabetes in ARIC in the low, intermediate and high genetic risk category was 33.2%, 41.3% and 47.2%, and in RS 22.8%, 30.6% and 35.5% respectively. The absolute lifetime risk for individuals with normal weight compared to individuals with obesity was 24% lower in ARIC and 8.6% lower in RS in the low genetic risk group, 36.3% lower in ARIC and 31.3% lower in RS in the intermediate genetic risk group, and 25.0% lower in ARIC and 29.4% lower in RS in the high genetic risk group. Conclusions: Genetic variants for type 2 diabetes have value in estimating the lifetime risk of type 2 diabetes. Normal weight mitigates partly the deleterious effect of high genetic risk.",

keywords = "BMI, lifetime risk, obesity, polygenic score, type 2 diabetes",

author = "Symen Ligthart and Hasbani, {Natalie R.} and Fariba Ahmadizar and {van Herpt}, {Thijs T.W.} and Leening, {Maarten J.G.} and Uitterlinden, {Andr{\'e} G.} and Sijbrands, {Eric J.G.} and Morrison, {Alanna C.} and Eric Boerwinkle and Pankow, {James S.} and Elizabeth Selvin and {Arfan Ikram}, M. and Maryam Kavousi and {de Vries}, {Paul S.} and Abbas Dehghan",

note = "Funding Information: The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL059367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The Rotterdam Study is supported by Erasmus MC and Erasmus University Rotterdam; Netherlands Organisation for Scientific Research (NWO); Netherlands Organisation for Health Research and Development (ZonMW); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative; Ministry of Education, Culture and Science; Ministry of Health, Welfa re and Sports; European Commission (DG XII); and Municipality of Rotterdam. None of the funders had any role in study design, study conduct; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. The dedication, commitment and contribution of inhabitants, general practitioners and pharmacists of the Ommoord district to the Rotterdam Study are gratefully acknowledged. PSdV and NRH were additionally supported by the American Heart Association grant number 18CDA34110116. Publisher Copyright: {\textcopyright} 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.",

year = "2021",

month = oct,

doi = "10.1111/dme.14639",

language = "English (US)",

volume = "38",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

TY - JOUR

T1 - Genetic susceptibility, obesity and lifetime risk of type 2 diabetes

T2 - The ARIC study and Rotterdam Study

AU - Ligthart, Symen

AU - Hasbani, Natalie R.

AU - Ahmadizar, Fariba

AU - van Herpt, Thijs T.W.

AU - Leening, Maarten J.G.

AU - Uitterlinden, André G.

AU - Sijbrands, Eric J.G.

AU - Morrison, Alanna C.

AU - Boerwinkle, Eric

AU - Pankow, James S.

AU - Selvin, Elizabeth

AU - Arfan Ikram, M.

AU - Kavousi, Maryam

AU - de Vries, Paul S.

AU - Dehghan, Abbas

N1 - Funding Information: The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL059367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The Rotterdam Study is supported by Erasmus MC and Erasmus University Rotterdam; Netherlands Organisation for Scientific Research (NWO); Netherlands Organisation for Health Research and Development (ZonMW); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative; Ministry of Education, Culture and Science; Ministry of Health, Welfa re and Sports; European Commission (DG XII); and Municipality of Rotterdam. None of the funders had any role in study design, study conduct; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. The dedication, commitment and contribution of inhabitants, general practitioners and pharmacists of the Ommoord district to the Rotterdam Study are gratefully acknowledged. PSdV and NRH were additionally supported by the American Heart Association grant number 18CDA34110116. Publisher Copyright: © 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

PY - 2021/10

Y1 - 2021/10

N2 - Aims: Both lifestyle factors and genetic background contribute to the development of type 2 diabetes. Estimation of the lifetime risk of diabetes based on genetic information has not been presented, and the extent to which a normal body weight can offset a high lifetime genetic risk is unknown. Methods: We used data from 15,671 diabetes-free participants of European ancestry aged 45 years and older from the prospective population-based ARIC study and Rotterdam Study (RS). We quantified the remaining lifetime risk of diabetes stratified by genetic risk and quantified the effect of normal weight in terms of relative and lifetime risks in low, intermediate and high genetic risk. Results: At age 45 years, the lifetime risk of type 2 diabetes in ARIC in the low, intermediate and high genetic risk category was 33.2%, 41.3% and 47.2%, and in RS 22.8%, 30.6% and 35.5% respectively. The absolute lifetime risk for individuals with normal weight compared to individuals with obesity was 24% lower in ARIC and 8.6% lower in RS in the low genetic risk group, 36.3% lower in ARIC and 31.3% lower in RS in the intermediate genetic risk group, and 25.0% lower in ARIC and 29.4% lower in RS in the high genetic risk group. Conclusions: Genetic variants for type 2 diabetes have value in estimating the lifetime risk of type 2 diabetes. Normal weight mitigates partly the deleterious effect of high genetic risk.

AB - Aims: Both lifestyle factors and genetic background contribute to the development of type 2 diabetes. Estimation of the lifetime risk of diabetes based on genetic information has not been presented, and the extent to which a normal body weight can offset a high lifetime genetic risk is unknown. Methods: We used data from 15,671 diabetes-free participants of European ancestry aged 45 years and older from the prospective population-based ARIC study and Rotterdam Study (RS). We quantified the remaining lifetime risk of diabetes stratified by genetic risk and quantified the effect of normal weight in terms of relative and lifetime risks in low, intermediate and high genetic risk. Results: At age 45 years, the lifetime risk of type 2 diabetes in ARIC in the low, intermediate and high genetic risk category was 33.2%, 41.3% and 47.2%, and in RS 22.8%, 30.6% and 35.5% respectively. The absolute lifetime risk for individuals with normal weight compared to individuals with obesity was 24% lower in ARIC and 8.6% lower in RS in the low genetic risk group, 36.3% lower in ARIC and 31.3% lower in RS in the intermediate genetic risk group, and 25.0% lower in ARIC and 29.4% lower in RS in the high genetic risk group. Conclusions: Genetic variants for type 2 diabetes have value in estimating the lifetime risk of type 2 diabetes. Normal weight mitigates partly the deleterious effect of high genetic risk.

KW - BMI

KW - lifetime risk

KW - obesity

KW - polygenic score

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85111707487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111707487&partnerID=8YFLogxK

U2 - 10.1111/dme.14639

DO - 10.1111/dme.14639

M3 - Article

C2 - 34245042

AN - SCOPUS:85111707487

SN - 0742-3071

VL - 38

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 10

M1 - e14639

ER -

Genetic susceptibility, obesity and lifetime risk of type 2 diabetes: The ARIC study and Rotterdam Study

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this